Publications | PubMed=3327702 Schoenberger O.L., Beikirch S., Trefz G., Drings P., Ebert W. Proteolytic activity of human tumor cell lines deriving from bronchial squamous cell carcinoma, pulmonary metastasis of rhabdomyosarcoma and pleural metastasis of mesothelioma. Eur. J. Respir. Dis. 71:434-443(1987) PubMed=3678487; DOI=10.1016/0014-5793(87)80413-1 Appelhans B., Ender B., Sachse G., Nikiforov T., Appelhans H., Ebert W. Secretion of antileucoprotease from a human lung tumor cell line. FEBS Lett. 224:14-18(1987) PubMed=2695238 Schoenberger O.L., Beikirch S. Cell cycle phases of two human lung tumor cell lines derived from squamous cell carcinoma and pulmonary metastasis of a rhabdomyosarcoma (HS 24 and HS 57) and N-acetylalanine aminopeptidase activity. Cancer Biochem. Biophys. 10:337-343(1989) PubMed=2201737; DOI=10.1177/38.9.2201737 Erdel M., Trefz G., Spiess E., Habermaas S., Spring H., Lah T., Ebert W. Localization of cathepsin B in two human lung cancer cell lines. J. Histochem. Cytochem. 38:1313-1321(1990) PubMed=2208054; DOI=10.1016/0165-4608(90)90141-V Erdel M., Peter W., Spiess E., Trefz G., Ebert W. Karyotypic characterization of established cell lines derived from a squamous cell carcinoma and an adenocarcinoma of human lung cancers. Cancer Genet. Cytogenet. 49:185-198(1990) PubMed=1316092 Erdel M., Spiess E., Trefz G., Boxberger H.-J., Ebert W. Cell interactions and motility in human lung tumor cell lines HS-24 and SB-3 under the influence of extracellular matrix components and proteinase inhibitors. Anticancer Res. 12:349-359(1992) PubMed=11414198; DOI=10.1007/s004320000207 Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127:375-386(2001) PubMed=14581340 Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin. Cancer Res. 9:4705-4713(2003) PubMed=15746151; DOI=10.1093/hmg/ddi092 Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum. Mol. Genet. 14:997-1007(2005) |